What's Happening?
Viridian Therapeutics, Inc. has entered into a Commercial Manufacturing Services Agreement with WuXi Biologics (Hong Kong) Limited. Under this agreement, WuXi Biologics will manufacture and supply Viridian's anticipated long-term supply requirements of
the drug substance and product for veligrotug, pending its approval for commercial use. WuXi Biologics will serve as a non-exclusive supplier, allowing Viridian to procure the product from other manufacturers as well. The agreement includes a provision for rolling forecasts of volume requirements, with a portion being a binding commitment. Pricing is volume-based, with the service fee fixed until the end of 2026, after which it may be adjusted annually. The agreement has an initial term of five years, with automatic renewals unless terminated by either party with 24 months' notice. Termination can also occur due to changes in law, material breaches, or insolvency.
Why It's Important?
This agreement is significant for Viridian Therapeutics as it secures a reliable manufacturing partner for veligrotug, a key product in their pipeline. The partnership with WuXi Biologics, a major player in the biologics manufacturing sector, ensures that Viridian can meet its future supply needs efficiently. This move is crucial for Viridian's strategic planning and market readiness, especially if veligrotug receives commercial approval. The volume-based pricing and flexible procurement options provide Viridian with cost management advantages and supply chain flexibility. This agreement could enhance Viridian's competitive position in the biopharmaceutical market, potentially leading to increased investor confidence and market share.
What's Next?
Looking ahead, Viridian will focus on obtaining the necessary approvals for veligrotug to commence commercial production. The company will also need to manage its forecasts and commitments under the agreement to optimize supply chain operations. Stakeholders, including investors and regulatory bodies, will be closely monitoring the progress of veligrotug's approval process and the execution of this manufacturing agreement. Any changes in regulatory environments or market conditions could impact the terms of the agreement or the strategic direction of Viridian.
